VIVORYON THERAPEUTICS N.V. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.798 EUR | +6.12% |
|
+0.38% | -90.20% |
| Apr. 24 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
| Mar. 15 | Vivoryon Therapeutics N.V Announces Resignation of Board of Directors | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 108.7 | 180 | 380.4 | 248.8 | 212.2 | 19.6 | - | - |
| Enterprise Value (EV) 1 | 108.7 | 154 | 365.7 | 218.6 | 193.7 | 0.0522 | 12.9 | 26.4 |
| P/E ratio | -8.77 x | -10.9 x | -30.2 x | -8.06 x | -7.27 x | -1.05 x | 0.91 x | 0.33 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 35.3 x | - | -58.6 x | - | - | - |
| EV / Revenue | - | - | 34 x | - | -53.5 x | - | - | - |
| EV / EBITDA | - | -9.71 x | -29 x | -7.55 x | -6.75 x | -0 x | -0.84 x | -1.54 x |
| EV / FCF | - | - | -32.4 x | -10 x | -17.6 x | -0 x | -0.93 x | -1.51 x |
| FCF Yield | - | - | -3.09% | -9.96% | -5.69% | -26,226% | -107% | -66.3% |
| Price to Book | - | - | - | 8.57 x | - | - | - | -1.07 x |
| Nbr of stocks (in thousands) | 19,975 | 19,975 | 20,020 | 24,105 | 26,067 | 26,067 | - | - |
| Reference price 2 | 5.440 | 9.010 | 19.00 | 10.32 | 8.140 | 0.7520 | 0.7520 | 0.7520 |
| Announcement Date | 3/26/20 | 4/30/21 | 4/28/22 | 4/19/23 | 4/24/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 10.76 | - | -3.62 | - | - | - |
| EBITDA 1 | - | -15.86 | -12.63 | -28.95 | -28.67 | -16.4 | -15.4 | -17.2 |
| EBIT 1 | - | -16.01 | -12.8 | -29.11 | -28.84 | -18.47 | 31.97 | 82.85 |
| Operating Margin | - | - | -118.9% | - | 796.6% | - | - | - |
| Earnings before Tax (EBT) 1 | - | -16.51 | -12.22 | -28.36 | -28.58 | -18.7 | 31.8 | 81.9 |
| Net income 1 | -7.823 | -16.51 | -12.66 | -28.16 | -28.34 | -18.7 | 19.13 | 54.45 |
| Net margin | - | - | -117.57% | - | 782.93% | - | - | - |
| EPS 2 | -0.6200 | -0.8300 | -0.6300 | -1.280 | -1.120 | -0.7167 | 0.8267 | 2.305 |
| Free Cash Flow 1 | - | - | -11.28 | -21.78 | -11.03 | -13.7 | -13.8 | -17.51 |
| FCF margin | - | - | -104.84% | - | 304.61% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 4/30/21 | 4/28/22 | 4/19/23 | 4/24/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2023 S2 |
|---|---|---|
| Net sales 1 | - | -3.62 |
| EBITDA | - | - |
| EBIT 1 | - | -18.14 |
| Operating Margin | - | 501.24% |
| Earnings before Tax (EBT) 1 | - | -17.82 |
| Net income 1 | -10.72 | -17.63 |
| Net margin | - | 486.91% |
| EPS 2 | -0.4400 | -0.6800 |
| Dividend per Share | - | - |
| Announcement Date | 9/7/23 | 4/24/24 |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | 6.8 |
| Net Cash position 1 | - | 26 | 14.7 | 30.1 | 18.5 | 19.6 | 6.7 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | -0.3953 x |
| Free Cash Flow 1 | - | - | -11.3 | -21.8 | -11 | -13.7 | -13.8 | -17.5 |
| ROE (net income / shareholders' equity) | - | - | -59.2% | -131% | -107% | -68.1% | -216% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | 1.200 | - | - | - | -0.7000 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 0.06 | 0.02 | 0.01 | 0.01 | - | - | - |
| Capex / Sales | - | - | 0.19% | - | -0.39% | - | - | - |
| Announcement Date | 3/26/20 | 4/30/21 | 4/28/22 | 4/19/23 | 4/24/24 | - | - | - |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.752
EUR
Average target price
41.57
EUR
Spread / Average Target
+5,427.48%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -90.20% | 21.31M | |
| +32.09% | 50.85B | |
| +0.84% | 42.82B | |
| +48.94% | 42.03B | |
| -4.22% | 29.55B | |
| +10.95% | 26.11B | |
| -21.72% | 19.13B | |
| +8.31% | 13.05B | |
| +26.74% | 12.16B | |
| +23.39% | 12.08B |
- Stock Market
- Equities
- VVY Stock
- Financials Vivoryon Therapeutics N.V.